New Real-World Data Supports Genentech’s Faricimab for DME
May 2, 2023
At this year’s annual ARVO conference, Genentech’s David Tabano, PhD, discussed new real-world data supporting the use of the company’s faricimab in the treatment of diabetic macular edema (DME), a progressive vision disorder affecting patients with diabetes. The data shows that patients taking faricimab maintained their vision over a 6 month period with 4 injections of the drug.
According to Tabano, “So we were able to identify patients who initiated faricimab between February and September of 2022, with follow-up through the end of the year. We identified roughly around 3100 DME patients who had received faricimab, both treatment naive and previously treated with other anti-VEGF agents. We found that the majority of these patients were previously treated with anti-VEGF mostly coming from aflibercept. We found that both treatment naive and previously treated patients came into starting faricimab with pretty good vision around 50%, across both sub cohorts had 20/40, or better vision when initiating faricimab. And among those who were previously treated, they were getting an average of around 5 anti-VEGF injections, and that prior treatment period at about 50ish days apart and other intervals.”
To read more, click here.
(Source: Ophthalmology Times, May 1st, 2023)
Tags: HEOR, RWD, RWE, Therapeutics, Ophthalmology